James Edgemond Sells 3,517 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 3,517 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $495.36, for a total transaction of $1,742,181.12. Following the completion of the sale, the chief financial officer owned 8,142 shares in the company, valued at $4,033,221.12. The trade was a 30.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, December 8th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $478.60, for a total transaction of $10,050,600.00.
• On Monday, December 1st, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $479.99, for a total value of $10,079,790.00.
• On Monday, November 24th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $473.64, for a total value of $9,946,440.00.
• On Monday, November 17th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $470.36, for a total value of $9,877,560.00.
• On Monday, November 10th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $452.07, for a total value of $9,493,470.00.
• On Tuesday, November 4th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $436.09, for a total value of $9,157,890.00.

United Therapeutics Stock Up 2.2%

Shares of UTHR opened at $510.94 on Thursday. The company has a market capitalization of $22.00 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 4.96 and a beta of 0.86. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $513.93. The stock has a 50 day moving average price of $460.85 and a 200 day moving average price of $378.34.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the previous year, the firm earned $6.39 EPS. The company’s revenue was up 6.8% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Several hedge funds have recently modified their holdings of UTHR. Chung Wu Investment Group LLC purchased a new stake in United Therapeutics during the second quarter worth about $29,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its stake in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. SVB Wealth LLC purchased a new stake in United Therapeutics during the 1st quarter worth about $32,000. Finally, Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on UTHR shares. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Royal Bank Of Canada boosted their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Oppenheimer raised their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 8th. Finally, HC Wainwright raised their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.